Loading…
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $1M | $-125M | $-140M | $-130M | -1752.2% | 550.0% | -108.3% |
| 2024 | $0M | $1.7B | $1.7B | $-197M | 1263.3% | -88.9% | - |
| 2023 | $2M | $-207M | $-241M | $-198M | -554.8% | 38.4% | - |
| 2022 | $1M | $-114M | $-115M | $-91M | 1579.8% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 1.30 | 1.80 | 0.20 | 1.30 |
| Operating Expense | 116.62 | 221.02 | 331.65 | 136.32 |
| Operating Income | -115.32 | -219.22 | -331.45 | -135.03 |
| EBITDA | -114.10 | -206.69 | 1,703.35 | -125.37 |
| EBIT | -115.32 | -207.88 | 1,701.07 | -127.86 |
| Pretax Income | -115.32 | -239.72 | 1,687.57 | -140.05 |
| Tax Provision | 0 | 0 | 0 | 0 |
| Net Income | -115.33 | -241.36 | 1,687.57 | -140.06 |
| Net Income Common Stockholders | -115.33 | -241.36 | 1,687.57 | -140.06 |
| Total Expenses | 116.62 | 221.02 | 331.65 | 136.32 |
| Interest Expense | 0 | 31.84 | 13.49 | 12.20 |
| Interest Income | 0 | 11.92 | 10.94 | 7.55 |
| Research And Development | 101.60 | 191.64 | 203.74 | 113.03 |
| Selling General And Administration | 15.04 | 29.38 | 127.50 | 23.12 |
| Normalized EBITDA | -114.10 | -206.69 | -318.15 | -125.37 |
| Normalized Income | -115.33 | -241.36 | -333.92 | -140.06 |
| Basic EPS | -8.10 | -16.95 | 114.01 | -9.04 |
| Diluted EPS | -8.10 | -16.95 | 112.62 | -9.04 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0.21 | 0.21 | 0 | 0.21 |
| Total Unusual Items | 0 | 0 | 2,021.50 | 0 |
| Total Unusual Items Excluding Goodwill | 0 | 0 | 2,021.50 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -115.33 | -241.36 | 1,687.57 | -140.06 |
| Reconciled Depreciation | 1.23 | 1.19 | 2.29 | 2.48 |
| Net Interest Income | 0 | -19.92 | -2.55 | -4.65 |
| Net Income From Continuing And Discontinued Operation | -115.33 | -241.36 | 1,687.57 | -140.06 |
| Total Operating Income As Reported | -115.32 | -219.22 | -331.45 | -135.03 |
| Diluted Average Shares | 14.24 | 14.24 | 14.98 | 15.49 |
| Basic Average Shares | 14.24 | 14.24 | 14.80 | 15.49 |
| Diluted NI Availto Com Stockholders | -115.33 | -241.36 | 1,687.57 | -140.06 |
| Net Income Including Noncontrolling Interests | -115.33 | -241.36 | 1,687.57 | -140.06 |
| Net Income Continuous Operations | -115.33 | -241.36 | 1,687.57 | -140.06 |
| Earnings From Equity Interest Net Of Tax | 0 | -1.63 | 0 | 0 |
| Other Income Expense | 0 | -0.58 | 2,021.57 | -0.38 |
| Other Non Operating Income Expenses | 0 | -0.58 | 0.07 | -0.38 |
| Special Income Charges | 0 | 0 | 2,021.50 | 0 |
| Restructuring And Mergern Acquisition | 0 | 0 | -2,021.50 | 0 |
| Net Non Operating Interest Income Expense | 0 | -19.92 | -2.55 | -4.65 |
| Interest Expense Non Operating | 0 | 31.84 | 13.49 | 12.20 |
| Interest Income Non Operating | 0 | 11.92 | 10.94 | 7.55 |
| Other Operating Expenses | -0.01 | 0 | 0 | 0 |
| Depreciation Amortization Depletion Income Statement | 0 | 0 | 0.40 | 0.18 |
| Depreciation And Amortization In Income Statement | 0 | 0 | 0.40 | 0.18 |
| General And Administrative Expense | 15.04 | 29.38 | 127.50 | 23.12 |
| Other Gand A | 15.04 | 29.38 | 127.50 | 23.12 |
| Operating Revenue | 1.30 | 1.80 | 0.20 | 1.30 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Inhibrx Biosciences, Inc.this co. | INBX | $1.8B | - | 227.77 | -1752.2% | -13.63 |
| GeneDx Holdings Corp. | WGS | $1.8B | - | 5.97 | -6.8% | 141.02 |
| Syndax Pharmaceuticals, Inc. | SNDX | $1.8B | - | 27.92 | -441.6% | -6.40 |
| Surgery Partners, Inc. | SGRY | $1.8B | - | 1.04 | -2.2% | 11.28 |
| AnaptysBio, Inc. | ANAB | $1.8B |
| - |
| 46.94 |
| -35.6% |
| 36.55 |
| Taysha Gene Therapies, Inc. | TSHA | $1.8B | - | 7.24 | -44.1% | -14.19 |
| Sonida Senior Living, Inc. | SNDA | $1.8B | - | -37500.00 | -125.8% | 57.41 |
| Harmony Biosciences Holdings, Inc. | HRMY | $1.8B | 11.23 | 2.05 | 18.2% | 4.68 |
| Palvella Therapeutics, Inc. | PVLA | $1.8B | - | 54.18 | -149.1% | - |
| Peer Median | - | 11.23 | 6.60 | -39.8% | 11.28 | |